VYNE Therapeutics Sees Positive Data for VYN201, VYN202

By Chris Wack VYNE Therapeutics said Monday that it saw positive data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with...

Related Keywords

,Chris Wack ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Biopharmaceuticals ,Biological Therapy ,Healthcare Provision ,Autoimmune Diseases ,Political General News ,Health ,Medical Conditions ,Synd ,Vyne Therapeutics ,Vyne ,Us92941v3087 ,Political ,General News ,Healthcare ,Life Sciences ,